• The 24-month follow-up data to be reported by the end of Q3
• The GMP production facility is generating revenue
• Adjusted for dilution, our fair value amounts to SEK 1.28 per share

Xintela’s half-year report did not reveal any surprises. As announced in Q1, XSTEM in knee osteoarthritis (OA) has been proven safe and tolerable by the 18-month data in all three dose levels. In Q2, the last patient in the phase I/IIa study was followed up. The complete 24-month data from the highest dose level is expected to be reported by the end of September.

Adjusted for dilution, our model suggests a fair value of SEK 1.28 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Läs mer på MFN